NewAmsterdam Pharma (NAMS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$7.1M

Revenue (quarter)

$3.7M

Revenue growth (year over year)

−80.67%

Gross profit (trailing twelve months)

$7.1M

Gross margin

100.00%

Net income (trailing twelve months)

−$259.5M

Net income (quarter)

−$64.1M

Net income growth (year over year)

−269.36%

Net margin

−3644.21%

Return on equity

−36.81%

EPS (trailing twelve months)

−$2.16

Book value per share

$5.37

P/E (trailing twelve months)

—

Price to book

4.02

Debt to assets

10.37%

Payout ratio

—

Dividend yield

—

Company profile

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

• Is NewAmsterdam Pharma (NAMS) profitable?

  No. NewAmsterdam Pharma reported a net loss of $259.5M over the trailing twelve months.

• How much revenue does NewAmsterdam Pharma (NAMS) make?

  NewAmsterdam Pharma generated $7.1M in revenue over the trailing twelve months, down 80.67% year over year.

• How do I buy stock in NewAmsterdam Pharma (NAMS)?

  NAMS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.